Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 12, 2026 07:30 ET | Source: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million ––...
January 12, 2026 07:00 ET | Source: First Watch Restaurant Group, Inc.

First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025

BRADENTON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch...
January 09, 2026 18:01 ET | Source: Ascendis Pharma

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones....
January 08, 2026 16:58 ET | Source: Ponce Financial Group, Inc.

Ponce De Leon Foundation Awarded Grants in the Amount of $635,000 to Nonprofits

BRONX, N.Y., Jan. 08, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of the Ponce De Leon Foundation is pleased to announce it has awarded $635,000 to nonprofits that are making a difference in our...
January 08, 2026 16:05 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
January 08, 2026 16:01 ET | Source: Pacira BioSciences

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira...
January 08, 2026 08:30 ET | Source: RenovoRx, Inc.

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows a...
January 08, 2026 08:00 ET | Source: Restem

RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026

MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today...
January 08, 2026 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)

Durham, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United StatesTherapy granted United States Food and Drug...
January 08, 2026 08:00 ET | Source: InflaRx N.V.

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)To broaden signal-finding activities for izicopan in...